We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

112 hedge funds and large institutions have $415M invested in Terns Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $1.16M | Put options by funds: $362K

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

9% more funds holding

Funds holding: 103 → 112 (+9)

6% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less capital invested

Capital invested by funds: $424M → $415M (-$9.03M)

7.86% less ownership

Funds ownership: 105.68% → 97.82% (-7.9%)

Holders
112
Holders Change
+9
Holders Change %
+8.74%
% of All Funds
1.61%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
27
Increased
36
Reduced
34
Closed
17
Calls
$1.16M
Puts
$362K
Net Calls
+$794K
Net Calls Change
-$539K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$19.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$14.5M
3
Millennium Management
Millennium Management
New York
+$9.43M
4
SSA
Schonfeld Strategic Advisors
New York
+$5.15M
5
OCA
Octagon Capital Advisors
New York
+$4.08M

Top Sellers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
-$29.2M
2
Morgan Stanley
Morgan Stanley
New York
-$18.7M
3
B
Braidwell
Connecticut
-$15M
4
VA
VR Adviser
New York
-$7.1M
5
PA
Perceptive Advisors
New York
-$6.98M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$2.77M +$1.33M +203,436 +93%
Northern Trust
27
Northern Trust
Illinois
$2.33M -$17.7K -2,708 -0.8%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$2.23M +$1.71M +262,192 +337%
MIM
29
Monashee Investment Management
Massachusetts
$1.97M +$1.96M +300,000 New
EP
30
Eversept Partners
New York
$1.86M +$1.85M +283,034 New
SCM
31
Silverarc Capital Management
Massachusetts
$1.64M -$1.74M -266,448 -52%
Barclays
32
Barclays
United Kingdom
$1.63M +$1.07M +163,722 +194%
BM
33
Bridger Management
New York
$1.62M +$1.61M +246,800 New
EAM
34
Exome Asset Management
New York
$1.49M +$1.49M +227,821 New
Goldman Sachs
35
Goldman Sachs
New York
$1.36M +$793K +121,395 +142%
SB
36
Samsara BioCapital
California
$1.33M – – –
Marshall Wace
37
Marshall Wace
United Kingdom
$1.22M +$1.21M +186,009 New
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.13M +$1.13M +172,599 New
N
39
Nuveen
North Carolina
$1.05M +$19.2K +2,940 +2%
Citigroup
40
Citigroup
New York
$1.03M +$983K +150,467 +2,121%
HS
41
HighVista Strategies
Massachusetts
$972K – – –
MA
42
MYDA Advisors
New York
$918K -$15.6K -2,383 -2%
Norges Bank
43
Norges Bank
Norway
$899K -$1.89M -289,600 -68%
Charles Schwab
44
Charles Schwab
California
$752K – – –
Bank of New York Mellon
45
Bank of New York Mellon
New York
$739K -$48.5K -7,430 -6%
IC
46
Ikarian Capital
Texas
$581K -$503K -76,983 -47%
PCM
47
Prelude Capital Management
New York
$555K +$553K +84,619 New
HF
48
HRT Financial
New York
$490K +$488K +74,755 New
Squarepoint
49
Squarepoint
New York
$468K +$466K +71,361 New
UBS Group
50
UBS Group
Switzerland
$412K -$298K -45,706 -42%
1
2
3 4 5

TERN Hedge Fund Activity: Q1 2024 in Review

112 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q1 2024, worth a combined $415M — down 2.1% from $424M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new TERN positions and 17 closed out — a net gain of 10 holders — while 36 added to existing stakes and 34 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $19.1M. The largest seller was Suvretta Capital Management, cutting an estimated $29.2M.

  • 112 institutional investors held Terns Pharmaceuticals (TERN) as of Q1 2024, up from 103 in Q4 2023.
  • Funds reported $415M of Terns Pharmaceuticals stock for Q1 2024, down 2.1% quarter-over-quarter.
  • 27 funds opened new Terns Pharmaceuticals positions in Q1 2024 and 17 closed out, a net change of +10 holders.
  • The largest Terns Pharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $19.1M added.
  • The largest Terns Pharmaceuticals seller in Q1 2024 was Suvretta Capital Management, an estimated $29.2M sold.

Based on aggregated 13F filings for Q1 2024.